CoChat

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAAα2,3subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

de Haas, S.L., de Visser, S.J., van der Post, J.P., Schoemaker, R.C., van Dyck, K., Murphy, M.G., de Smet, M., Vessey, L.K., Ramakrishnan, R., Xue, L., Cohen, A.F., van Gerven, J.M.A. · 2008 · Journal of Psychopharmacology
Cited by 104

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered by unfavourable side effects. some of these may be associated with binding properties to certain subtypes of the GABA A receptor that are unnecessary for therapeutic effects. MK-0343 was designed to be a less sedating anxiolytic, based on reduced efficacy at the α1 subtype and significant efficacy at α2 and α3 subtypes of the GABA A receptor. This paper is a double-blind, four-way cross-over ( n = 12) study to investigate the effects of MK-0343 (0.25 and 0.75 mg) in comparison to placebo and an anxiolytic dose (2 mg) of the non-selective agonist lorazepam. Effects were measured by eye movements, body sway, Visual Analogue scales (VAs) and memory tests. Lorazepam impaired saccadic peak velocity (sPV), VAs alertness scores, postural stability and memory and increased saccadic latency and inaccuracy. MK-0343 0.75 mg was equipotent with lorazepam as indicated by sPV (-42.4 deg/s), saccadic latency (0.02 s) and VAs alertness scores (1.50 ln mm), while effects on memory and postural stability were smaller. MK-0343 0.25 mg only affected postural stability to a similar extent as MK-0343 0.75 mg. The effect profile of MK-0343 0.75 mg is different from the full agonist lorazepam, which could reflect the selective actions of this compound. Although less effect on VAs alertness was expected, diminished effects on memory and postural stability were present. Clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881107082108

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 104

Metadata

Authors
de Haas, S. L., de Visser, S. J., van der Post, J. P., Schoemaker, R. C., van Dyck, K., Murphy, M. G., de Smet, M., Vessey, L. K., Ramakrishnan, R., Xue, L., Cohen, A. F., & van Gerven, J. M. A.
Venue
Journal of Psychopharmacology
Published
2007-08-22
Volume
22
Issue
1
Pages
24-32
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2016154588
Cited by
104
References
11
FWCI
5.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAAα2,3subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. https://app.cochat.ai/papers/10.1177/0269881107082108
The paper
de Haas, S. L., de Visser, S. J., van der Post, J. P., Schoemaker, R. C., van Dyck, K., Murphy, M. G., de Smet, M., Vessey, L. K., Ramakrishnan, R., Xue, L., Cohen, A. F., & van Gerven, J. M. A. (2008). Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAAα2,3subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. Journal of Psychopharmacology. https://doi.org/10.1177/0269881107082108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.